Piotr Wysocki: Relatlimab does not improve the activity of nivolumab plus chemotherapy
Piotr Wysocki recently posted on LinkedIn:
“RELATIVITY-060 was an open-label phase II study investigating the benefit of adding relatlimab (anti-LAG3 antibody) to standard first-line treatment (XELOX/FOLFOX+nivolumab) in previously untreated gastric or gastroesophageal junction adenocarcinoma (GEJ) patients.
The study randomized 461 patients (2:1) to nivolumab+chemotherapy+relatlimab (NCR) or nivolumab+chemotherapy (NC). The primary endpoint was the objective response rate (ORR by BCIR) in patients with LAG-3-positive tumors (expression ≥1%).
After a median follow-up of 11.9 months, the results were as follows:
- ORR in LAG3+ patients – 48% (NCR) and 61% (NC)
- ORR in the ITT population – 43% (NCR) and 60% (NC)
- Median PFS (LAG+) – 7.0 months (NCR) and 8.3 months (NC) – HR=1.41 (95%CI 0.97-2.05)
- Median PFS (ITT) – 6.8 months (NCR) and 9.4months (NC) – HR=1.61 (95%CI 1.18-2.20)
- Median OS – 13.5 months (NCR) and 16.0 months (NC) – HR=1.03 (95%CI 0.70-1.54)
- Median OS – 12.4 months (NCR) and 15.5 months (NC) – HR=1.32 (95%CI 0.96-1.83)
The RELATIVITY-060 study confirms that nivolumab+XELOX/FOLFOX remains the treatment of choice in first-line settings in gastric or GEJ adenocarcinoma patients (especially those with CPS>5%).
Moreover, relatlimab worsened outcomes of gastric or GEJ adenocarcinoma patients, even in the case of LAG3-positive tumors.”
Authors: Susanna Hegewisch-Becker, Guillermo Mendez, Joseph Chao, Kynan Feeney, Eric Van Cutsem, Salah-Eddin Al-Batran, Wasat Mansoor, Nicholas Maisey, Roberto Pazo Cid, Matthew Burge, David Perez-Callejo, R. William Hipkin, Sourav Mukherjee, Ming Lei, Hao Tang, Satyendra Suryawanshi, Ronan J. Kelly, Niall Tebbutt
Source: Piotr Wysocki/LinkedIn
Piotr Wysocki leads the Clinical Oncology Department at University Hospital and the Faculty of Oncology at Jagiellonian University-Medical College in Krakow, Poland. As an advisor to the Polish Ministry of Health, he shapes the national cancer strategy.
His clinical expertise spans the systemic treatment of breast, gynecologic, and genitourinary cancers, with a focus on developing innovative metronomic chemotherapy-based therapies for advanced cancer patients who have undergone prior treatment.
Read other posts by Piotr Wysocki published on OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023